Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract

Cancer risk of weight-loss drugs that activate the glucagon-like peptide-1 receptor compared to bariatric surgery and other treatments

Updated

Abstract

Obesity is associated with an increased risk of several cancers, including colorectal cancer, pancreatic cancer, and hepatocellular carcinoma.

  • Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may lower the risk of certain cancers related to obesity.
  • Most existing studies have focused on patients with diabetes rather than those using GLP-1 RAs for weight loss.
  • The effects of GLP-1 RAs on nondiabetic patients remain unclear.

Simplified

Full Text

Full text is available at the source.

Funding

Competing interests

0 of 9
authors report competing interests
9 report none
PubMed

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free